==== Front Cell Death Dis Cell Death Dis Cell Death & Disease 2041-4889 Nature Publishing Group UK London 3245 10.1038/s41419-020-03245-8 Review Article Neurotensin pathway in digestive cancers and clinical applications: an overview http://orcid.org/0000-0003-2125-0503Christou Niki christou.niki19@gmail.com 12 Blondy Sabrina 1 http://orcid.org/0000-0002-2260-6690David Valentin 13 Verdier Mireille 1 Lalloué Fabrice 1 Jauberteau Marie-Odile 14 Mathonnet Muriel 12 http://orcid.org/0000-0001-7882-0613Perraud Aurélie 12 1 grid.9966.00000 0001 2165 4861Laboratoire EA3842 CAPTuR « Contrôle de l’Activation cellulaire, Progression Tumorale et Résistances thérapeutiques », Faculté de médecine, 2 rue du Docteur Marcland, 87025 Limoges, France 2 grid.411178.a0000 0001 1486 4131Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, 2 avenue Martin Luther King, 87042 Limoges, France 3 grid.411178.a0000 0001 1486 4131Service de Pharmacie, CHU de Limoges, 2 avenue Martin Luther King, 87042 Limoges, France 4 grid.411178.a0000 0001 1486 4131Service d’Immunologie, CHU de Limoges, 2 avenue Martin Luther King, 87042 Limoges, France 2 12 2020 2 12 2020 12 2020 11 12 10272 6 2020 1 11 2020 2 11 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Initially, NEUROTENSIN (NTS) has been shown to play physiological and biological functions as a neuro-transmitter/modulator in the central nervous system and as an endocrine factor in the periphery, through its binding to two kinds of receptors: NTSR1 and 2 (G protein-coupled receptors) and NTSR3/sortilin (a vacuolar protein-sorting 10-domain receptor). NTS also plays oncogenic roles in many types of cancer, including digestive cancers. In tumor tissues, NTS and NTSR1 expression is higher than in healthy ones and is associated with poor prognosis. NTS and NTRS1 promote cancer progression and play key functions in metastatic processes; they modulate several signaling pathways and they contribute to changes in the tumor microenvironment. Conversely, NTRS2 involvement in digestive cancers is poorly understood. Discovered for mediating NTS biological effects, sortilin recently emerged as a promising target as its expression was found to be increased in various types of cancers. Because it can be secreted, a soluble form of sortilin (sSortilin) appears as a new serum biomarker which, on the basis of recent studies, promises to be useful in both the diagnosis and tumor progression monitoring. More precisely, it appears that soluble sortilin can be associated with other receptors like TRKB. These associations occur in exosomes and trigger the aggressiveness of cancers like glioblastoma, leading to the concept of a possible composite theranostic biomarker. This review summarizes the oncogenic roles of the NTS signaling pathways in digestive cancers and discusses their emergence as promising early diagnostic and/or prognostic biomarkers and therapeutic targets. Subject terms CancerGastrointestinal cancerissue-copyright-statement© The Author(s) 2020 ==== Body Facts Digestive cancers are frequent; colorectal cancer is the third most common cancer worldwide. NEUROTENSIN (NTS) known as both a neurotransmitter/modulator in the central nervous system and a hormone in the periphery, has recently been shown to be involved in the digestive carcinogenesis process. NTS and its receptors, NTSR1–2 and sortilin/NTSR3 might emerge as potential diagnostic, prognostic, and therapeutic biomarkers. Open questions What NTS and their receptors correspond to? What are their roles in physiological processes? What are their roles in pathological processes such as cancers and, specifically, digestive cancers? Introduction NEUROTENSIN (NTS) is a neurotransmitter/modulator in the central nervous system and a hormone in the periphery1,2. It is released by endocrine cells in the intestinal mucosa, metabolized by the liver and is involved in several functions of the gastrointestinal tract3. NTS is able to inhibit gastric acid secretion and to modulate gut motility, depending on the type of muscle and its localization (ascending/descending colon, circular, and other smooth muscles) but it also acts on mucosa proliferation4,5. Cell growth in digestive organs (stomach, colon, pancreas, and small bowel mucosa) is possible thanks to NTS6 stimulation through its binding to two G protein-coupled receptors (GPCRs), neurotensin receptors (NTSR) 1 and 2, and through a third receptor, NTSR3/sortilin7–9, a member of the vacuolar protein sorting 10 (Vps10)-related domain-containing protein family10 (Fig. 1). Vps10 domain-containing receptors, which are typical transmembrane proteins, include three members with sortilin, a sorting-related receptor with A-type repeats (sorLA) and sortilin-related Vps10 domain-containing receptors. Sortilin, the most studied of them, is known to be involved in neurodegenerative and inflammatory diseases and immunologic processes as well, through its key role in protein cell sorting, trafficking, and releasing, including NTS and NTSR111,12. A soluble form of sortilin (sSortilin)13 has also been detected and identified as a promising biomarker in CRC14,15. Initially reported in breast carcinoma16,17, NTS and its receptors are also linked to the development and progression of multiple cancer types, including digestive cancers18. Recently, a clinical trial has highlighted increased NTS plasma levels in patients with colon cancer in comparison with healthy individuals and especially those bearing noncancerous polyps, thus suggesting that these levels might be of diagnosis value19. In addition, NTS pathway emerged to play crucial roles in migration and invasion processes, which are prerequisites to metastatic spread, and in inflammation processes associated with tumor microenvironment modulation20. Hence, they could constitute potential targets for the development of anticancer drugs21–23. A recent patent (US20170218057A1) has been deposited that relates an antineurotensin long fragment antibody, which is able to bind NTS with high affinity and to neutralize its oncogenic properties24. However, this antibody has not yet been tested on colorectal cancer cells.Fig. 1 Receptors of neurotensin (NTSRs). Three receptors of NTS are known: two of them are G-protein-coupled receptors (GPCRs): NTSR1 with high affinity for NTS, and NTSR2 with low affinity. The third one is a Vacuolar protein sorting 10 (Vps10) related domain protein family receptor named NTSR3 (sortilin). This review focuses on NTS and its receptors, NTSR1–2 and sortilin/NTSR3. It aims to underline their potential use as diagnostic, prognostic and therapeutic biomarkers and targets in digestive (gastric, pancreatic, hepatic, and colorectal) cancers. NTS and NTSRs: related signaling pathways and biological processes NTS is a 13 amino acids (aa) neuropeptide evidenced in 1973 by Carraway and Leeman in bovine hypothalamus extracts and identified in neurodegenerative diseases (Parkinson and Huntington diseases)1. More recently, it has also been detected in the neuroendocrine system of the gastro-intestinal tract (oesophageal gastric, pancreatic, and colonic cells), where it exerts secretory25, proliferative/trophic and motility actions4. NTS biological effects are mainly mediated by two GPCRs26: NTSR1 (410 aa, 56 kDa), the high-affinity NTS receptor (Kd = 0.15–0.5 nM), and NTSR2 (418 aa, 62 kDa), the low-affinity NTS receptor (Kd = 5–7 nM), which possesses 64% homology with NTSR1. Whereas NTS/NTSR2 signaling pathway is not yet fully understood, that of NTS/NTSR1 is well known. NTS binding to the Gαq11 subunit of NTSR1 triggers phospholipase C-γ (PLC-γ) activation, whose activity leads to the production of inositol trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol-4,5-bisphosphate. IP3 and DAG respectively trigger the mobilization of intracellular Ca2+ and activation of protein kinase-C (PKC). PKC then activates the mitogen-activated protein kinase (MAPK)-extracellular signal–regulated kinases (ERK1/2) pathway independently of RAS, via direct stimulation of RAF-1. Active PKC also activates protein kinase D which in turn leads to the activation of the nuclear factor-kappa B (NFκB) transcription factor. MAPK-ERK1/2 pathway activates transcription factors, such as the activator protein 1 (AP-1) complex, NFκB, early growth response protein 1 (Egr-1), the ternary complex factor (TCF) Elk-1, and c-myc, allowing cell survival and proliferation27–29. NTS also induces activation of Rho GTPases, the focal adhesion kinase (FAK) and the proto-oncogene tyrosine-protein kinase Src, hence modulating cytoskeleton dynamics and cell migration18 (Fig. 2).Fig. 2 Simplified scheme of the NTS signaling pathways involving NTSR1 and sortilin, and biological effects associated. NTS binds to NTSR1, either alone or complexed with sortilin at the cell membrane, and activates four main pathways: (i) Rho GTPases, (ii) intracellular Ca2+ release, (iii) PKC/RAF-1/MAPK-ERK1/2, and (iv) PI3K/AKT. Then, each one of these targets activates downstream effectors and transcription factors which participate in the transcription of genes involved in cell survival and proliferation, as well as in cytoskeleton dynamics and cell migration. Sortilin can be cleaved and released from the plasma membrane as a soluble form (sSortilin) that, after being internalized, directly stimulates FAK ERK1/2 extracellular signal–regulated kinases, FAK focal adhesion kinase, MAPK mitogen-activated protein kinase, NTS neurotensin, NTSR1 neurotensin receptor 1, PKC protein kinase C, PI3K phosphtidylinositol 3-kinase, sSortilin soluble form of sortilin. While most of NTS mitogenic effects are mainly mediated by NTSR1, the roles played by sortilin/NTSR3 in this context are yet unclear. Sortilin (831 aa, 95–110 kDa) is, together with sorLA and sorCS1–3, a member of the Vps10 domain receptor family21,30. If sortilin binds a wide variety of ligands including neurotrophins (NT), progranulin, lipoproteins, and apolipoproteins or the glucose transporter isoform 4, it presents a much higher affinity for NTS, which therefore impairs the binding of all of the other ligands31. It has been suggested that sortilin is able to directly induce signaling after NTS binding, promoting migration of microglial cells31. However, mechanisms by which NTS/sortilin binding induces signal transduction are still unclear and poorly understood. To date, sortilin involvement in the modulation of NTS pro-survival signaling pathway has been mainly evidenced through its three main roles: (i) a scavenger, when expressed to the cell membrane, through the binding, internalization32 and degradation of its ligands30, (ii) a regulator of intracellular traffic and secretion of its ligands and their receptors30,33, (iii) receptor and coreceptor, displacing ligands (including NTS and NT) from their specific receptors34, and thus enhancing the associated biological responses30,35,36. Like all Vps10-related domain protein family members, sortilin can be cleaved and released as a soluble form (sSortilin) from the plasma membrane through PKC-dependent mechanisms. The roles and functions of sSortilin are not yet completely elucidated. This protein could act as a decoy that would prevent the binding of ligands to their specific receptors, but could also be internalized and/or bound to a yet unknown receptor to participate in the metastatic process in CRC, through FAK activation (Fig. 2), thus activating the phosphoinositide 3-kinase (PI3K)/AKT pathway15,18,30,37,38. Many studies have demonstrated NTS oncogenic activities (cell survival, proliferation, migration, and invasion), in an endocrine, autocrine and/or paracrine manner, in several types of cancers and at each step of cancer progression. NTSR1 is involved in tumor progression in many cancers, including digestive cancers21,39–41. NTSR2 has been reported to be involved in prostatic cancer, chronic lymphocytic leukaemia42,43 and glioma44, but little is known about NTS/NTSR2 action mechanisms involved in the progression of cancers. Finally, alteration of sortilin expression and/or its cellular functions leads to a deregulation of biological processes, thus contributing to the development of lipid disorders, neurodegenerative and inflammatory diseases12,45–47 and cancerous diseases33,48. Although the NTS pathway has not yet been studied in oesophageal squamous cell carcinoma, numerous studies have been performed on gastric, pancreatic, hepatic and colon tumors, relating (i) how NTS and its receptors could be involved in cancer development and progression, and (ii) why they might be promising pharmacological targets and biomarkers in cancer therapy, as summarized below. Oncogenic roles of NTS and NTSR in digestive cancers Gastric cancer Gastric cancer (GC) is the fourth most common malignant tumor in the world49 with half of the incidence linked to Asian people. The most frequent type of gastric cancer is adenocarcinoma. Its development is triggered by different factors, especially chronic inflammation with possible infectious substratum (Helicobacter pylori infections). Surgical resection, associated with standardized lymphadenectomy, remains the gold standard treatment50. While its incidence declines because of higher standards of hygiene, healthier diet and H. pylori eradication, this cancer becomes symptomatic only at an advanced stage. Evidencing of new serum biomarkers allowing early diagnosis would be of significant benefit. In addition, the overall survival rate of patients with advanced gastric adenocarcinomas remains low, despite the use of new targeted agents like the human epidermal growth-factor receptor 2 (HER2) antibody (trastuzumab)51. It is noteworthy that positive HER2 expression has been detected in less than 20% of these patients52. While neither NTSR2 nor sortilin have been studied in GC cells, NTS and NTSR1 expressions are associated with poor prognosis. NTSR1 expression is higher in tumor than in healthy tissues53,54, and is correlated with the most advanced pathological grade and pTNM (pathology Tumor Nodes Metastases) stages55. However, this latter clinical study by Zygulska et al., does not show any correlation between NTSR1 tumoral tissue expression level and age, sex or Lauren Classification (histological classification of adenocarcinoma between “intestinal-type” and “diffuse-type”). In a previous study, higher NTSR1 expression with higher pTNM grade, corresponding to a diffuse type, according to Lauren’s Classification, associated with a higher pathological grade has been significantly correlated with poorer prognosis. In vitro and in vivo studies have shown NTS and NTSR implication in cancer cell migration and invasion via activation of PKC, ERK1/2 and PI3K signaling pathways. Moreover, NTS plasma concentration and metalloproteinase (MMP)-9 activity, are positively correlated, and found at higher levels in GC patients compared to controls56. Inhibition of NTSR1 expression by a NTSR1 antagonist or the knockdown of the NTSR1 gene leads to a significant decrease of MMP-9 expression and activity54. These findings suggest that NTSR1 could be a potential therapeutic target for the treatment of gastric cancer. Pancreatic cancer Pancreatic ductal adenocarcinoma (PDAC) is the fourth cause of cancer-related death and is the most lethal of common malignancies in the world with poor 5-year survival rate (less than 10%), due to complex and delayed diagnosis57. Thus, therapeutic options are limited, and surgery is not always possible. Better knowledge of risk factors and actors of pancreatic carcinogenesis is needed to get earlier diagnosis and to improve the efficiency of the therapeutic protocols. By 2030, PDAC could become the second leading cause of cancer-related death in the United States58. As early as 1998 it was shown that both NTS and NTSR1 were higher expressed in PDAC tissues as compared with non-cancerous ones59, and higher expression levels strongly correlate with increasing pathological grades60,61. Moreover, higher NTSR1 expression is found in primary tumors and liver metastases of invasive pancreatic cancers62. In PDAC cell lines, NTS stimulates ERK1/2 and AKT pathways dependently of PKC activation and independently of EGFR transactivation63–65. NTS-mediated PKC activation stimulates RAF-1, which activates the MAPK-ERK1/2 cascade; phosphorylated ERK1/2 is able to translocate to the cell nucleus and then to promote the growth of the PDAC cell line29,64–66. NTS-mediated PDAC cell growth and proliferation are pharmacologically inhibited by SR48692, a NTS receptor antagonist60. A NTSR-specific Positron Emission Tomography (PET) has been developed thanks to a NTSR-directed fluorinated ligand. This method has demonstrated its diagnostic capacity in evaluating NTRS1-positive PDAC. Furthermore, a personalized NTRS-targeted therapy using PET has been created67,68 which has shown its feasibility and whose preliminary results are encouraging69. Sortilin has been detected in PDAC cells in which NTS triggers pro-tumor and pro-metastatic effects70. NTS modulates the migration properties of human PDAC cells in vitro. These effects are mediated through NTS binding to sortilin and depend of whether the cells migrate individually or collectively. Indeed, migration levels of collectively migrating PDAC are decreased whereas those of individually migrating cells are increased. Mechanistically, expression of integrins is altered, resulting in modifications of both adhesion cell properties and actin cytoskeleton organization, mediated by NTS-dependent RhoGTPases activation71. Hepatic cancer Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide with over 500,000 diagnosed patients each year72. Rapid progressive clinical course, poor response to conventional treatments and poor clinical outcomes are characteristic of HCC. Treatments available are surgery, percutaneous destruction or hepatic transplantation. Metastatic stages can be addressed with tyrosine kinase inhibitors (TKI; sorafenib, lenvatinib and regorafenib)73 or with transcatheter arterial chemoembolization. Most patients are diagnosed with advanced stages of the disease and, unfortunately, are not eligible for curative surgery74. NTS and NTSR1 are coexpressed at high levels in more than 50% of HCC (NTSR1 being only weakly expressed in normal tissues); this coexpression correlates with aggressive biological behaviors: increase of EMT (epithelio-mesenchymal transition) features, e.g., decreased E-Cadherin expression and increased N-Cadherin and nuclear β-Catenin expressions. NTS and NTSR1 are thus associated with poor prognosis and clinical outcomes in HCC patients75,76. NTS effects on EMT induction and tumor invasion are mediated by aberrant activation of both the NTSR1 and Wnt/β-Catenin pathways. In vitro, EMT is abolished when NTSR1-overexpressing HCC cells are treated with the NTSR1 antagonist SR48692 or specific inhibitors of the Wnt/β-Catenin pathway as TSW119 or Dick kopf-1. In vivo, the same inhibitors prevent the formation of metastases in mice bearing NTSR1-overexpressing HCC xenografts75. NTSR1 activation by NTS, either produced in HCC cells expressing NTSR1 and NTS, or secreted—and transported - by the hepatic portal vein, leads to the stimulation of the Wnt/β-Catenin signaling pathway. Nuclear β-Catenin then activates the transcription of target genes, including NTSR1 and EGFR. It results (i) a sustained autocrine signaling loop via NTSR1 and (ii) a sustained expression and activation of EGFR and its downstream effectors (such as ERK1/2), thus promoting tumor progression and invasion. On the other hand, the sustained expression and activation of EGFR presents somewhat beneficial effects since it restores and increases the cellular sensitivity to TKI such as erlotinib or sorafenib76. Finally, the NTS pathway also plays key roles in the modulation of tumor microenvironment and the maintenance of HCC stem cells, through the regulation of pro-inflammatory/angiogenesis cytokines production and expression. In CD133-positive HCC stem cells, NTS stimulates and increases the expression and production of interleukin (IL)-8 and chemokine (C-X-C motif) ligand 1 (CXCL1), through activation of the RAF-1/ERK1/2 pathways, resulting in the building of the autocrine IL-8 signaling loop which promotes tumor angiogenesis, tumorigenesis and the self-renewal abilities of HCC cells77. Mechanistically, NTS stimulates IL-8 production and expression through activation of the MAPK and NFκB pathways. HCC-derived IL-8 induced upon NTS stimulation (i) attracts pro-inflammatory cells (CD28 + macrophages, CD66b + polynuclear neutrophils) to the local microenvironment, triggers an increased formation of pro-inflammatory cytokines and promotes phagocytosis, and (ii) stimulates the polarization of tumor-associated macrophages (TAMs), indirectly promoting EMT and enhances the invasive potential of HCC cells. All of these effects, mediated via activation of the NTS/IL-8 pathway, have been observed in vitro and in vivo; they are significantly reduced after the blockade of IL-8 and NTS receptors78,79. In summary, NTS pathway plays crucial functions in the progression of HCC, by promoting invasion, EMT, metastasis formation, stem cells maintenance and by influencing the pro-oncogenic and inflammatory tumor microenvironment. In the future, NTSR1 could constitute a theranostic biomarker, whose evaluation might be useful to select TKI-eligible patients76. In addition, targeting the NTS/IL-8 pathway could also be promising in order to prevent HCC tumor progression, metastasis formation along with HCC stem cells maintenance. Colorectal cancer With over 1.8 million new cases in 2018, CRC is the third most commonly occurring cancer worldwide (third in men and second in women) and the second cause of cancer-related death (over 880,000 deaths)72. Histological analyses have shown that Liberkhünien Adenocarcinomas are the most frequently found among CRC patients. Three distinct classifications of CRC have been established that take into account tumor heterogeneity; the different classes have been linked to patients’ prognosis80: (i) classification according to stages, i.e., the tumor damage of the different layers of the colonic wall (pTNM), (ii) histological classification, i.e., according to the state of differentiation of tumors, and, more recently, (iii) the molecular classification (cancer subtyping consortium or CMS). pTNM and histological classification are currently used, whereas CMS classification is rather oriented toward prognosis and personalized therapeutic decisions81–83. Therapeutic management of CRC is based on surgical resection when the tumor is well localized, accompanied with adjuvant chemotherapy (5-FU, oxaliplatin and folinic acid) for high-risk stage II and stage III patients, that is to say patients whose risk factors are associated with a high recurrence rate and a poor prognosis [lymphovascular invasion, BRAFV600E hotspot mutation, MSS status84, KRAS mutated, presence of signet ring cell or mucinous histologic subtypes85]. For patients with advanced and metastatic CRC, chemotherapy “called neoadjuvant” is associated with treatments that mainly target the vascular endothelial growth factor and the epidermal growth factor (EGF) pathways86. Despite improvements in screening campaigns, earlier patient diagnosis, better prognosis evaluation and therapeutic management, 4 out of 5 CRC patients are still diagnosed at too advanced a stage, so they are unlikely to benefit from surgery. In 70% of cases, diagnosis is made at stages II or III and one-third of the treated patients suffer from recurrence within 2 years, which irreparably leads to the formation of metastases87–89. Therefore, new biomarkers are needed to allow (i) earlier detection of CRC and (ii) better, more specific and more efficient treatments, in order to overcome CRC and current therapeutic resistances. Concerning diagnosis, a clinical study found that plasmatic NTS rate higher than 54.47 pg/mL, with a sensitivity of 77% and a specificity of 90%, could differentiate patients with CRC from controls90. More prospective cohorts are necessary to confirm this result. Focusing on NTSR1, its promoter methylation91 or acetylation41 status could explain high NTSR1 gene and protein expression level in CRC. In a nutshell, the characterization of both NTSR1 gene and protein expressions could confirm the diagnosis of CRC and link it to a specific sub-type, thus forming a molecular signature. It is noteworthy that it is deacetylation of NTSR1 promoter by histone deacetylase inhibitors (HDACi, e.g., sodium butyrate), (i) that alters NTSR1 mRNA and protein expression as well as its promoter activity. This is mediated through GSK3-β nuclear expression increase, (ii) with a decrease in ERK1/2 activation induced by NTS and (iii) consequently leads to the attenuation of the expression of some NTS-induced genes involved in colon tumorigenesis, cell proliferation and malignant transformation (e.g., COX2, c-myc, and IL-8). These results highlight that downregulation of NTSR1 may represent a promising mechanism to target CRC through either HDACi or GSK3-β and ERK1/2 inhibitors41. NTS pathway involvement in CRC tumor growth and cell proliferation has been highlighted since more than 20 years ago23,28,40,92–94. The majority of CRC cells are sensitive to NTS, which triggers growth responses by preferentially interacting with NTSR1 and/or sortilin, these two receptors being expressed in all CRC cells70. In vitro study published in 2015, focusing on human colorectal cancer cell lines corresponding to different colorectal cancer stages, showed variable NTS and NTSR1 expressions, no expression of NTSR2 and constant NTSR3 expression95. NTSR1 expression in adenocarcinoma is correlated with diffuse cytoplasmic or nuclear β-catenin localization40. Early stages of CRC development are characterized by mutations in the APC gene leading to a reinforced nuclear localization and increased expression of TCF/β-catenin. TCF/β-catenin then binds to the NTSR1 promoter region and consequently triggers expression of this gene40. Reciprocally, NTSR1 also regulates β-Catenin activation and function40,96,97. NTS, through its binding to NTSR1, is able to stimulate the MAPK-ERK1/2 downstream signaling pathway which promotes the expression and activation of transcription factors such as c-fos, a member of AP-1 complex, and Elk1, which activates genes that are involved in cell growth and proliferation. NTSR1 inhibition by a selective antagonist (SR48692) inhibits tumor growth in vivo and cell proliferation in vitro, thus confirming the oncogenic effects of NTS which acts in both the autocrine and paracrine ways98. Moreover, signaling mechanisms mediating NTS effects involve multiple pathways and are cellular-dependent. In CRC (and contrary to PDAC), NTS can stimulate the ERK1/2 and AKT pathways through two different ways depending on cell lines99. In HT29, NTS-induced ERK1/2 and AKT activation is dependent on EGFR transactivation, but at the same time is PKC-independent. EGFR inhibition by gefitinib blocks NTS-induced activation of both the ERK1/2 and AKT pathways64. In HCT116, ERK1/2 activation and subsequent DNA synthesis are PKC-dependent, while PI3K/AKT activation is mainly EGFR transactivation-dependent64. Rho GTPases family which includes RhoA, Rac1 and Cdc42, are also key proteins involved in NTS oncogenic effects. NTS induces the expression of IL-8, in nontransformed human colonic epithelial cells and in CRC cells, and expression and secretion of IL-8 are both mediated through RhoGTPases-dependent NFκB activation. While these mechanisms are complex and not yet well understood, it has been observed that: (i) NTS rapidly activates the RhoGTPases RhoA, Rac1 and Cdc42, (ii) these RhoGTPases activated by NTS are necessary to activate the transcription factor NFκB and (iii) thus NFκB activated is required to trigger IL-8 production, expression and secretion100. In addition to RhoGTPases, IL-8 secretion would also depend on the release of intracellular Ca2+ and RAS-MEK1/2-ERK1/2 activation, the both of them being induced upon NTS stimulation. Indeed, the IL-8 promoter region contains binding sites for NFκB, but also for c-jun and c-fos (AP-1 complex) which are both activated downstream of ERK1/2 activation101. While the NTS pathway could possibly play a role in the modulation of CRC microenvironment through IL-8 regulation102,103, as compared with HCC, this hypothesis deserves further investigation. Expressed by the majority of CRC cells, the heterodimer NTSR1/sortilin modulates intracellular responses induced by NTS34,104. In the absence of NTS, this heterodimer is largely expressed at the plasma membrane. In the presence of NTS, it is internalized, leading to a decrease of membrane-bound NTSR1 while the total amount of membrane-bound sortilin remains unchanged. Moreover, NTSR1 remains bound to sortilin during internalization. Mechanistically, heterodimerization changes the functional properties of NTSR1 but not its ability to bind NTS. Indeed, ERK1/2 activation induced by NTS is lower in cells coexpressing both NTSR1 and sortilin. These changes in signaling responses induced by NTS between cells coexpressing NTSR1/sortilin and those expressing NTSR1 alone, would result from the conformational changes of NTSR1 induced by its binding to sortilin. Sortilin binding would hinder further association of NTSR1 with intracellular proteins (β-arestin and G protein-q), thus perturbing activation of downstream signaling pathways34. However, NTS/NTSR1/sortilin complex internalization would be necessary for ERK1/2 activation but not for IP3 formation and PKC activation, ERK1/2 and PKC pathways being activated upon NTS stimulation from independent mechanisms104. Finally, sortilin embedded in the plasma membrane can be cleaved (by shedding of its extracellular domain) via PKC-dependent MMP activation upon external stimuli, resulting in the formation of sSortilin, a functional soluble form of the protein. sSortilin is then either internalized or released in the extracellular medium. In this later case, in an autocrine and paracrine manner, sSortilin stimulates a yet unknown receptor and promotes the modification of cancer cell shape, followed by initiation of their separation and spreading14,15 (Fig. 3):sSortilin/unknown receptor complex promotes a disruption of desmosome architecture and a disorganization of actin filaments. sSortilin/unknown receptor complex stimulates FAK/Src pathways to increase integrin mRNA levels and to decrease E-Cadherin protein expression, leading to the detachment of the cell from other cells and from the extracellular matrix, thus leading to the formation of metastasis. sSortilin/unknown receptor complex activates FAK/Src pathways which can also stimulate PI3K/AKT activation and Ca2+ release, promoting cell survival and cell proliferation. Fig. 3 Sortilin and its soluble form (sSortilin) in colorectal cancer. Altogether these data suggest that NTSR1 overexpression may represent an early event of colonic carcinogenesis, promoting CRC development and progression97, and might be a promising diagnostic and prognostic biomarker, and a potential therapeutic target to overcome chemotherapeutic resistances105. In addition, sSortilin displays key roles in the first step of the metastatic process15. Therefore, a better understanding of the molecular mechanisms involved in its functions could allow its targeting to prevent metastasis formation in CRC. In this way, the blockade of sortilin cleavage through targeting of MMP activity constitutes a new challenge: in vitro, the metalloprotease ADAM10 inhibitor (BB3103) totally blocked sSortilin production in the HT29 cell line13. Thus, targeting MMP to prevent both sSortilin and metastasis formation is promising106, but requires more investigations such as the development of selective inhibitors for specific MMPs and for each subtype of colorectal cancer. Discussion and remarks NTS pathway displays important anti-apoptotic and pro-oncogenic effects, associated with tumor development, progression and metastasis formation in many types of cancer, e.g., digestive cancers. However, nothing has yet been found about NTS involvement in oesophageal cancer. Expression of the couple NTS/NSTR appears to promote tumor progression and aggressiveness in digestive cancers, and more especially colorectal cancer. More clinical studies are needed to correlate each subtype of CRC with the expression levels of both NTS and NTSR. Indeed, these levels could constitute signatures of each subtype of CRC, thus allowing to define the prognosis of each entity and to trigger personalized therapies in a way similar to what has been done for breast cancer in relation with the HER2 status107. While NTSR2 expression has not been found in any of the digestive cancers, NTSR3/sortilin has mainly been studied and described in PDAC and CRC. This third NTSR plays key roles in the first step of the metastatic process, promoting EMT induction, cell migration and invasion. In CRC, sortilin, as well as its soluble form (sSortilin), may constitute a promising diagnostic, prognostic and therapeutic resistance biomarker. Its screening and targeting would thus be useful in clinical applications. However, more investigations are needed to better understand the molecular mechanisms involved in sortilin/sSortilin-mediated oncogenic effects in digestive cancers. NTS and its high-affinity receptor NTSR1 are the most described and studied in digestive cancers. Both of them are overexpressed in tumors and this overexpression is associated with poor prognosis, since they are involved in each step of cancer progression. The numerous molecular mechanisms through which the NTS/NTSR1 complex mediates oncogenic effects are complex and different in each cancer cell-type and thus they must be more precisely and individually elucidated (Table 1). Nevertheless, NTS and NTSR1 might be very promising diagnostic, prognostic and therapeutic targets. Their screening and targeting may be useful for clinical applications by acting on primary tumors and migrating cancer cells, but also on the tumor microenvironment via the modulation of the IL-8 pathway, as observed in HCC and CRC. Indeed, production and secretion of IL-8 by tumor cells are induced by NTS and have an impact upon the tumor microenvironment. Besides the pro-inflammatory effects, IL-8 also triggers EMT and promotes cancer cell migration and invasion, as well as HCC stem cells maintenance. In addition, IL-8 attracts some stromal cells from the tumor microenvironment, e.g., neutrophils and TAMs, which also contribute to tumor progression by inducing EMT. Therefore, targeted therapies blocking either NTSR1 or IL-8 receptors may be effective to inhibit EMT process, thus preventing tumor progression and metastasis. In view of the importance of tumor microenvironment actors in cancer progression and of the growing emergence of immunotherapy, it becomes of the greatest interest to understand how NTS could influence the tumor microenvironment of digestive cancers and more particularly the perineural invasion (the network of peripheral nerves which connects the TME to the central nervous system, also involved in cancer cell dissemination)108. NTSR1 blocking becomes a major challenge in many studies. Several options have been described and tested in vitro and/or in vivo in digestive cancer models. Among them, a NTSR1 pharmacological antagonist (SR48692) has proved interesting, by inhibiting tumor growth and cancer cell proliferation and survival. Moreover, HDACi, e.g., NaBT, suppresses endogenous NTSR1 expression with efficient antitumor effects in CRC cell lines. Interestingly, studies have also demonstrated that curcumin, a naturally occurring polyphenolic pigment with chemopreventive and/or chemotherapeutic properties, inhibits the NTS/IL-8 pathway and thus CRC HCT116 cell line migration103.Table 1 NTS, NTSR, downstream signaling pathways and main molecular mechanisms related to primary tumors, EMT and tumor microenvironement, and involved in each of the four digestive cancers described (GC, PDAC, HCC, and CRC). NTS and receptors Activated signaling pathways, downstream stimulated effectors and upregulated genes Tumor microenvironment modulation (NTS/IL-8) GC NTS (secreted), NTSR1 - PKC - ERK1/2 - PI3K/AKT Not described PDAC 1- NTS, NTSR1 2- NTS/sortilin - PKC-dependent ERK1/2 - PI3K/AKT RhoGTPases Not described HCC NTS, NTSR1 Wnt/β-catenin → NTSR1, EGFR Stem cells maintenance RAF-1, ERK1/2 → IL-8, CXCL1 EMT, cancer, and stromal cell infiltration within tumors MAPK, NFκB → IL-8 CRC 1- NTS, NTSR1 2- sortilin/sSortilin (secreted) - PKB, β-catenin → Cyclin D1 - Ca2+ release - RhoGTPases, NFκB → IL-8 - AKT by EGFR-transactivation dependent (HT29, HCT116) - MAPK-ERK1/2 by EGFR-transactivation dependent (HT29) or PKC-activation dependent (HCT116) → AP-1, Elk1, Egr1 activation → IL-8, EGFR - FAK/Src - Ca2+ release Not described CRC colorectal cancer, EGFR epidermal growth factor receptor, Egr-1 early growth response protein 1, ERK1/2 extracellular signal–regulated kinases 1/2, FAK focal adhesion kinase, GC gastric cancer, HCC hepatocellular carcinoma, IL interleukin, MAPK mitogen-activated protein kinase, NFκB nuclear factor-kappa B, NTS neurotensin, NTSR neurotensin receptor, PDAC pancreatic ductal adenocarcinoma, PI3K phosphatidylinositol 3-kinase, PKB protein kinase B, PKC protein kinase C, UR unknown receptor. To summarize, this review focused on oncogenic roles of NTS and its receptors in digestive cancers and highlighted their use as putative diagnostic, prognostic and therapeutic biomarkers. NTS/NTSR1 is the best described and studied couple of molecules: the both of them are overexpressed in digestive cancers and are associated with poor prognosis. Thus, NTS and NTSR1 are promising candidates for digestive cancers clinical screening and targeting. Recently, some studies conducted on PDAC67,69,109–111 and CRC112,113 have developed radiopharmaceuticals targeting NTSR1 for diagnostic and therapeutic application. Radiolabeled peptide and non-peptide tracers have been designed which are promising PET imaging probes for diagnosis, allowing the discrimination between patients with PDAC and those who only suffer from pancreas inflammation. In addition, a radiopharmaceutical treatment with NTSR1 antagonist has recently shown its feasibility and has led to encouraging results from a symptomatic and oncological point of view, albeit with a small cohort size (13 patients)69. The clinical trial NCT03525392, is presently recruiting patients with solid tumors (in particular, gastric cancers, CRC and PDAC) in order to evaluate the safety and efficacy of a radiopharmaceutical treatment using the radiolabeled NTSR1antagonist 177Lu-3BP-227. These recent findings must be developed in the future and they will undoubtedly open new promising insights in NTS pathway targeting in digestive cancers. Edited by F. Pentimalli Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Niki Christou, Sabrina Blondy Acknowledgements We thank La Ligue Nationale contre le Cancer for funding the 4th year of Sabrina BLONDY’s thesis and La Ligue contre le Cancer Comité de la Haute-Vienne and CORC “Comité d’Orientation Recherche en Cancer” from Limousin for financial support. Dr. Michel Guilloton is acknowledged for his help in manuscript editing. This work was supported and funded by grants from the Limousin Regional Council, La Ligue Nationale Contre le Cancer (Comité Départemental de La Haute-Vienne), and CORC (Comité d’Orientation de la Recherche en Cancérologie) from Limoges. Conflict of interest The authors declare that they have no conflict of interest. ==== Refs References 1. Carraway R Leeman SE The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami J. Biol. Chem. 1973 248 6854 6861 4745447 2. Carraway R Leeman SE Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach J. Biol. Chem. 1976 251 7045 7052 993203 3. Ferris CF Carraway RE Hammer RA Leeman SE Release and degradation of neurotensin during perfusion of rat small intestine with lipid Regul. Pept. 1985 12 101 111 10.1016/0167-0115(85)90191-0 3840906 4. Mustain WC Rychahou PG Evers BM The role of neurotensin in physiologic and pathologic processes Curr. Opin. Endocrinol. Diabetes Obes. 2011 18 75 82 10.1097/MED.0b013e3283419052 21124211 5. Zhao D Pothoulakis C Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation Peptides 2006 27 2434 2444 10.1016/j.peptides.2005.12.016 16872719 6. Kitabgi P Neurotensin: specific binding to synaptic membranes from rat brain Proc. Natl Acad. Sci. 1977 74 1846 1850 10.1073/pnas.74.5.1846 266706 7. Morris NJ Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes J. Biol. Chem. 1998 273 3582 3587 10.1074/jbc.273.6.3582 9452485 8. Mazella J The 100-kDa neurotensin receptor Is gp95/Sortilin, a non-g-protein-coupled receptor J. Biol. Chem. 1998 273 26273 26276 10.1074/jbc.273.41.26273 9756851 9. Petersen CM Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography J. Biol. Chem. 1997 272 3599 3605 10.1074/jbc.272.6.3599 9013611 10. Evers BM Neurotensin stimulates growth of colonic mucosa in young and aged rats Gastroenterology 1992 103 86 91 10.1016/0016-5085(92)91099-P 1612361 11. Glerup S Nykjaer A Vaegter CB Sortilins in neurotrophic factor signaling Handb. Exp. Pharmacol. 2014 220 165 189 10.1007/978-3-642-45106-5_7 24668473 12. Talbot H Regulatory roles of sortilin and SorLA in immune-related processes Front. Pharmacol. 2019 9 1507 10.3389/fphar.2018.01507 30666202 13. Navarro V Vincent J-P Mazella J Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line Biochem. Biophys. Res. Commun. 2002 298 760 764 10.1016/S0006-291X(02)02564-0 12419319 14. Massa F Focal adhesion kinase dependent activation of the PI3 kinase pathway by the functional soluble form of neurotensin receptor-3 in HT29 cells Int. J. Biochem. Cell Biol. 2013 45 952 959 10.1016/j.biocel.2013.01.020 23395631 15. Béraud-Dufour S Focal adhesion kinase-dependent role of the soluble form of neurotensin receptor-3/sortilin in colorectal cancer cell dissociation Int. J. Mol. Sci. 2016 17 1860 10.3390/ijms17111860 16. Crcss AS Azzopardi JG Krausz T Noorden SV Polak JM A morphological and immunocytochemical study of a distinctive variant of ductal carcinoma in-situ of the breast Histopathology 1985 9 21 37 10.1111/j.1365-2559.1985.tb02968.x 2579885 17. Dupouy S The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression PLoS ONE 2009 4 e-4223 10.1371/journal.pone.0004223 19156213 18. Ouyang Q Oncogenic role of neurotensin and neurotensin receptors in various cancers Clin. Exp. Pharmacol. Physiol. 2017 44 841 846 10.1111/1440-1681.12787 28556374 19. Qiu S Exploratory analysis of plasma neurotensin as a novel biomarker for early detection of colorectal polyp and cancer Horm. Cancer 2019 10 128 135 10.1007/s12672-019-00364-3 31093954 20. Ye, Y. et al. Neurotensin, a Novel Messenger to Cross-Link Inflammation and Tumor Invasion via Epithelial-Mesenchymal Transition Pathway. Int. Rev. Immunol.1–11 (2014). 10.3109/08830185.2014.952412. 21. Wu Z Martinez-Fong D Trédaniel J Forgez P Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy Front. Endocrinol. 2013 3 184 10.3389/fendo.2012.00184 22. Dorsam RT Gutkind JS G-protein-coupled receptors and cancer Nat. Rev. Cancer 2007 7 79 94 10.1038/nrc2069 17251915 23. Liu, Aihua, Zuo, Z., Liu, Linlin & Liu, Lihua. Down-regulation of NTSR3 inhibits growth, metastasis, and PI3K/AKT and MAPK signaling pathways in colorectal cancer cells. Biochem. Cell Biol. (2020). 10.1139/bcb-2019-0351. 24. Forgez, P. Anti-neurotensin long fragment antibodies and uses thereof. United States patent 10, 174, 106B2 (2019). 25. Sakamoto T Role of neurotensin in pancreatic secretion Surgery 1984 96 146 153 6463855 26. Vincent J-P Mazella J Kitabgi P Neurotensin and neurotensin receptors Trends Pharmacol. Sci. 1999 20 302 309 10.1016/S0165-6147(99)01357-7 10390649 27. Zhao D Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells Int. J. Cancer J. Int. Cancer 2007 120 1652 1656 10.1002/ijc.22407 28. Ehlers RA Bonnor RM Wang X Hellmich MR Evers BM Signal transduction mechanisms in neurotensin-mediated cellular regulation Surgery 1998 124 239 246 10.1016/S0039-6060(98)70126-6 9706144 29. Ehlers RA Zhang Y Hellmich MR Evers BM Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2 Biochem. Biophys. Res. Commun. 2000 269 704 708 10.1006/bbrc.2000.2335 10720480 30. Mazella J Vincent J-P Functional roles of the NTS2 and NTS3 receptors Peptides 2006 27 2469 2475 10.1016/j.peptides.2006.04.026 16872720 31. Martin S Vincent J-P Mazella J Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia J. Neurosci. 2003 23 1198 1205 10.1523/JNEUROSCI.23-04-01198.2003 12598608 32. Nielsen MS Jacobsen C Olivecrona G Gliemann J Petersen CM Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase J. Biol. Chem. 1999 274 8832 8836 10.1074/jbc.274.13.8832 10085125 33. Wilson CM The implications of Sortilin/Vps10p domain receptors in neurological and human diseases CNS Neurol. Disord. - Drug Targets. 2014 13 1354 1365 10.2174/1871527313666141023151642 25345507 34. Martin S Navarro V Vincent JP Mazella J Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line Gastroenterology 2002 123 1135 1143 10.1053/gast.2002.36000 12360476 35. Wilson CM Sortilin mediates the release and transfer of exosomes in concert with two tyrosine kinase receptors J. Cell Sci. 2014 127 3983 3997 10.1242/jcs.149336 25037567 36. Blondy S Neurotrophins and their involvement in digestive cancers Cell Death Dis. 2019 10 123 10.1038/s41419-019-1385-8 30741921 37. Glerup, S., Nykjaer, A. & Vaegter, C. B. Sortilins in Neurotrophic Factor Signaling. In Neurotrophic Factors (eds. Lewin, G. R. & Carter, B. D.) vol. 220 165–189 (Springer Berlin Heidelberg, 2014). 38. Meldolesi J Neurotrophin receptors in the pathogenesis, diagnosis and therapy of neurodegenerative diseases Pharmacol. Res. 2017 121 129 137 10.1016/j.phrs.2017.04.024 28438600 39. Dupouy S The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers Biochimie 2011 93 1369 1378 10.1016/j.biochi.2011.04.024 21605619 40. Souazé F Neurotensin receptor 1 gene activation by the Tcf/β-catenin pathway is an early event in human colonic adenomas Carcinogenesis 2006 27 708 716 10.1093/carcin/bgi269 16299383 41. Wang X Jackson LN Johnson SM Wang Q Evers BM Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers Mol. Cancer Ther. 2010 9 2389 2398 10.1158/1535-7163.MCT-09-1080 20663927 42. Abbaci, A. et al. Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis. Oncogene (2017). 10.1038/onc.2017.365. 43. Saada S Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes J. Immunol. 2012 189 5293 5303 10.4049/jimmunol.1102937 23109725 44. Ayala-Sarmiento AE Martinez-Fong D Segovia J The internalization of neurotensin by the low-affinity neurotensin receptors (NTSR2 and vNTSR2) activates ERK 1/2 in glioma cells and allows neurotensin-polyplex transfection of tGAS1 Cell. Mol. Neurobiol. 2015 35 785 795 10.1007/s10571-015-0172-z 25772140 45. Gao A Implications of sortilin in lipid metabolism and lipid disorder diseases DNA Cell Biol. 2017 36 1050 1061 10.1089/dna.2017.3853 28945101 46. Goettsch C Kjolby M Aikawa E Sortilin and its multiple roles in cardiovascular and metabolic diseases Arterioscler. Thromb. Vasc. Biol. 2018 38 19 25 10.1161/ATVBAHA.117.310292 29191923 47. Carlo A-S The pro-neurotrophin receptor sortilin is a major neuronal APOE receptor for catabolism of amyloid-β peptide in the brain J. Neurosci. 2013 33 358 370 10.1523/JNEUROSCI.2425-12.2013 23283348 48. Wilson CM A new role under sortilin’s belt in cancer Commun. Integr. Biol. 2016 9 e1130192 10.1080/19420889.2015.1130192 27066187 49. Sitarz R Gastric cancer: epidemiology, prevention, classification, and treatment Cancer Manag. Res. 2018 10 239 248 10.2147/CMAR.S149619 29445300 50. Stomach Cancer Surgery | Stomach Cancer Operation. https://www.cancer.org/cancer/stomach-cancer/treating/types-of-surgery.html. 51. Bang Y-J Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 2010 376 687 697 10.1016/S0140-6736(10)61121-X 20728210 52. Abrahao-Machado LF Scapulatempo-Neto C HER2 testing in gastric cancer: An update World J. Gastroenterol. 2016 22 4619 4625 10.3748/wjg.v22.i19.4619 27217694 53. Zhou Z The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer Diagn. Pathol. 2015 10 128 10.1186/s13000-015-0356-3 26215716 54. Akter H Yoon JH Yoo YS Kang M-J Validation of neurotensin receptor 1 as a therapeutic target for gastric cancer Mol. Cells 2018 41 591 602 29794962 55. Zygulska AL Furgala A Kaszuba-Zwoińska J Krzemieniecki K Gil K Changes in plasma levels of cholecystokinin, neurotensin, VIP and PYY in gastric and colorectal cancer – Preliminary results Peptides 2019 122 170148 10.1016/j.peptides.2019.170148 31541684 56. Akter H Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer Tumor Biol. 2015 36 6053 6062 10.1007/s13277-015-3282-9 57. Drouillard A Manfredi S Lepage C Bouvier A-M Épidémiologie du cancer du pancréas Bull. Cancer 2018 105 63 69 10.1016/j.bulcan.2017.11.004 29273548 58. Rahib L Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res. 2014 74 2913 2921 10.1158/0008-5472.CAN-14-0155 24840647 59. Reubi J Waser B Friess H Buchler M Laissue J Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma Gut 1998 42 546 550 10.1136/gut.42.4.546 9616318 60. Wang J-G Li N-N Li H-N Cui L Wang P Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1 Neuropeptides 2011 45 151 156 10.1016/j.npep.2011.01.002 21272935 61. Wang L Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease Clin. Cancer Res. 2000 6 566 571 10690540 62. Körner M Waser B Strobel O Büchler M Reubi JC Neurotensin receptors in pancreatic ductal carcinomas EJNMMI Res. 2015 5 17 10.1186/s13550-015-0094-2 25859423 63. Guha S Rey O Rozengurt E Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1 Cancer Res. 2002 62 1632 1640 11912133 64. Müller KM Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells BMC Cancer 2011 11 421 10.1186/1471-2407-11-421 21961726 65. Guha S Lunn JA Santiskulvong C Rozengurt E Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1 Cancer Res. 2003 63 2379 2387 12750255 66. Ryder NM Guha S Hines OJ Reber HA Rozengurt E G protein–coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation† J. Cell. Physiol. 2001 186 53 64 10.1002/1097-4652(200101)186:1<53::AID-JCP1004>3.0.CO;2-Q 11147814 67. Wang M Development of [18F]AlF-NOTA-NT as PET agents of neurotensin receptor-1 positive pancreatic cancer Mol. Pharm. 2018 15 3093 3100 10.1021/acs.molpharmaceut.8b00192 29889537 68. Hodolic M Ambrosini V Fanti S Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer Nucl. Med. Commun. 2020 41 411 415 10.1097/MNM.0000000000001172 32168264 69. Baum RP 177Lu-3BP-227 for neurotensin receptor 1–targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results J. Nucl. Med. 2018 59 809 814 10.2967/jnumed.117.193847 29025990 70. Dal Farra C Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines Int. J. Cancer 2001 92 503 509 10.1002/ijc.1225 11304684 71. Mijatovic T Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration Cell. Oncol. J. Int. Soc. Cell. Oncol. 2007 29 315 326 72. Bray F Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA. Cancer J. Clin. 2018 68 394 424 10.3322/caac.21492 30207593 73. Treatment of Liver Cancer, by Stage. https://www.cancer.org/cancer/liver-cancer/treating/by-stage.html. 74. El-Serag HB Hepatocellular Carcinoma N. Engl. J. Med. 2011 365 1118 1127 10.1056/NEJMra1001683 21992124 75. Ye Y NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma Oncotarget 2016 7 70303 70322 10.18632/oncotarget.11854 27611941 76. Wu Z Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib Cancer Lett. 2017 388 73 84 10.1016/j.canlet.2016.11.032 27914862 77. Tang KH CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling Hepatology 2012 55 807 820 10.1002/hep.24739 21994122 78. Xiao P Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells Oncoimmunology 2018 7 e1440166 10.1080/2162402X.2018.1440166 29900041 79. Yu J Dysfunctional Activation of Neurotensin/IL-8 Pathway in Hepatocellular Carcinoma Is Associated with Increased Inflammatory Response in Microenvironment, More Epithelial Mesenchymal Transition in Cancer and Worse Prognosis in Patients PLoS ONE 2013 8 e56069 10.1371/journal.pone.0056069 23418512 80. Singh, M. P., Rai, S., Pandey, A., Singh, N. K. & Srivastava, S. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine. Genes Dis. (2019). 10.1016/j.gendis.2019.10.013. 81. Barresi V Reggiani Bonetti L Ieni A Caruso RA Tuccari G Histological grading in colorectal cancer: new insights and perspectives Histol. Histopathol. 2015 30 1059 1067 26004398 82. Guinney J The consensus molecular subtypes of colorectal cancer Nat. Med. 2015 21 1350 1356 10.1038/nm.3967 26457759 83. Brierley, J. D., Gospodarowicz, Ma. K. & Wittekind, C. TNM Classification of Malignant Tumours, 8th Edition. 83. (Wiley publisher, 2017). 84. Seppälä TT Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer Br. J. Cancer 2015 112 1966 1975 10.1038/bjc.2015.160 25973534 85. Liska D Incidence, patterns, and predictors of locoregional recurrence in colon cancer Ann. Surg. Oncol. 2017 24 1093 1099 10.1245/s10434-016-5643-z 27812826 86. Roock WD Vriendt VD Normanno N Ciardiello F Tejpar S KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer Lancet Oncol. 2011 12 594 603 10.1016/S1470-2045(10)70209-6 21163703 87. Stein A Atanackovic D Bokemeyer C Current standards and new trends in the primary treatment of colorectal cancer Eur. J. Cancer 2011 47 S312 S314 10.1016/S0959-8049(11)70183-6 21943995 88. André T Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to braf mutation and mismatch repair status of the MOSAIC Study J. Clin. Oncol. 2015 33 4176 4187 10.1200/JCO.2015.63.4238 26527776 89. André, T. & Cohen, R. Cancer colorectal: traitements adjuvants. FMC-HGE.https://www.fmcgastro.org/texte-postu/postu-2018-paris/cancer-colorectal-traitements-adjuvants/ (2018). 90. Sgourakis G The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer Tumour Biol. 2014 35 5993 6002 10.1007/s13277-014-1794-3 24627130 91. Kamimae S Epigenetic silencing of NTSR1 is associated with lateral and noninvasive growth of colorectal tumors Oncotarget 2015 6 29975 29990 10.18632/oncotarget.5034 26334593 92. Maoret J-J Anini Y Rouyer-Fessard C Gully D Laburthe M Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice Int. J. Cancer 1999 80 448 454 10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N 9935189 93. Evers BM Ishizuka J Chung DH Townsend CM Thompson JC Neurotensin expression and release in human colon cancers Ann. Surg. 1992 216 423 431 10.1097/00000658-199210000-00005 1329682 94. Qiu S A review of the role of neurotensin and its receptors in colorectal cancer Gastroenterol. Res. Pract. 2017 2017 6456257 10.1155/2017/6456257 28316623 95. Kim JT Weiss HL Evers BM Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells Int. J. Oncol. 2017 50 2200 2206 10.3892/ijo.2017.3990 28498396 96. Fodde R Smits R Clevers H APC , signal transduction and genetic instability in colorectal cancer Nat. Rev. Cancer 2001 1 55 67 10.1038/35094067 11900252 97. Gui X Guzman G Dobner PR Kadkol SS Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma Peptides 2008 29 1609 1615 10.1016/j.peptides.2008.04.014 18541341 98. Gully D Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor Proc. Natl Acad. Sci. USA. 1993 90 65 69 10.1073/pnas.90.1.65 8380498 99. Massa F Tormo A Béraud-Dufour S Coppola T Mazella J Neurotensin-induced Erk1/2 phosphorylation and growth of human colonic cancer cells are independent from growth factors receptors activation Biochem. Biophys. Res. Commun. 2011 414 118 122 10.1016/j.bbrc.2011.09.034 21945442 100. Zhao D Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-κB pathways Am. J. Physiol. -Cell Physiol. 2003 284 C1397 C1404 10.1152/ajpcell.00328.2002 12584113 101. Zhao D Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes J. Biol. Chem. 2001 276 44464 44471 10.1074/jbc.M104942200 11574537 102. Ning Y Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models Int. J. Cancer 2011 128 2038 2049 10.1002/ijc.25562 20648559 103. Wang X Wang Q Ives KL Evers BM Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells Clin. Cancer Res. 2006 12 5346 5355 10.1158/1078-0432.CCR-06-0968 17000667 104. Navarro V Martin S Mazella J Internalization-dependent regulation of HT29 cell proliferation by neurotensin Peptides 2006 27 2502 2507 10.1016/j.peptides.2006.04.028 16870305 105. Bugni JM The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer Int. J. Cancer 2012 130 1798 1805 10.1002/ijc.26208 21630261 106. Cathcart J Pulkoski-Gross A Cao J Targeting matrix metalloproteinases in cancer: bringing new life to old ideas Genes Dis. 2015 2 26 34 10.1016/j.gendis.2014.12.002 26097889 107. Harbeck N Gnant M Breast cancer Lancet Lond. Engl. 2017 389 1134 1150 10.1016/S0140-6736(16)31891-8 108. Jobling P Nerve–cancer cell cross-talk: a novel promoter of tumor progression Cancer Res. 2015 75 1777 1781 10.1158/0008-5472.CAN-14-3180 25795709 109. Prignon A Preclinical evaluation of 68Ga-DOTA-NT-20.3: a promising pet imaging probe to discriminate human pancreatic ductal adenocarcinoma from pancreatitis Mol. Pharm. 2019 16 2776 2784 10.1021/acs.molpharmaceut.9b00283 31013092 110. Emrarian I Sadeghzadeh N Abedi SM Abediankenari S New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification Chem. Biol. Drug Des. 2018 91 304 313 10.1111/cbdd.13082 28816013 111. Yin X Evaluation of neurotensin receptor1 as a potential imaging target in pancreatic ductal adenocarcinoma Amino Acids 2017 49 1325 1335 10.1007/s00726-017-2430-5 28536844 112. Lang C Maschauer S Hübner H Gmeiner P Prante O Synthesis and evaluation of a 18f-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors J. Med. Chem. 2013 56 9361 9365 10.1021/jm401491e 24160350 113. Jia Y Zhang W Fan W Brusnahan S Garrison J Investigation of the biological impact of charge distribution on a NTR1-targeted peptide Bioconjug. Chem. 2016 27 2658 2668 10.1021/acs.bioconjchem.6b00418 27661393